Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENVISION: UBX1325 in Wet AMD
NCT05275205Phase 2Completed
- Sponsor
- Unity Biotechnology
- Start
- Mar 2022
- Primary completion
- Feb 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of foselutoclax in neovascular age-related macular degeneration (NVAMD), sponsored by Unity Biotechnology. Started Mar 2022; status: completed.
02
Drugs
foselutoclax
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05275205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275205.